Lung Cancer

• Diagnosis, Imaging, Screening
• General Information
• Guidelines
• Internet Sites
• Risk Factors
• Risk Reduction
• Treatment - Daily Report

Lung Cancer is a new InfoMedSearch topic - started January 1, 2007.

Treatment is updated daily with the most recent articles listed on top.
To view only the last month's articles for the other sub-topics, go to our Monthly Online Newsletters page

If you have any questions regarding our Search Reports, please contact us at info@infomedsearch.com.

Lung Cancer

Mayo Clinic Lung Cancer

"Lung cancer is the leading cause of cancer deaths in the United States, among both men and women. It claims more lives than colon, prostate, lymph and breast cancer combined. Yet most of these lung cancer deaths could have been prevented. That's because smoking accounts for nearly 90 percent of lung cancer cases. … Because lung cancer doesn't cause signs or symptoms in its earliest stages, it's often advanced by the time it's diagnosed. When symptoms do occur, the most common warning sign is a cough, which occurs when a tumor irritates the lining of the airways or blocks the passage of air. In addition to a new cough, be alert for: • "Smoker's cough" that worsens • Coughing up blood, even a small amount • Chest pain • Shortness of breath • New onset of wheezing • Repeated bouts of pneumonia or bronchitis • Hoarseness that lasts more than two weeks Lung cancer also may cause fatigue, loss of appetite and weight loss. If it has spread to other parts of your body (metastasized), you may have headaches or bone pain."

Highlighted Article

CancerHelp UK - Types of lung cancer

"There are important differences between lung cancer that started in the lungs and lung cancer that has spread to the lung from another part of the body. … Primary lung cancer (cancer that has started in the lungs) There are several different types of primary lung cancer. These are divided into two main types • Small cell lung cancer • Non-small cell lung cancer ... Secondary lung cancer (cancer that has spread to the lungs) Secondary cancer is cancer that has spread from somewhere else in the body. There are quite a few different cancers that can spread to the lungs, including breast cancer and bowel cancer."

CONTINUE YOUR INFOMEDSEARCH RESEARCH with our previous InfoMedLinks. Start with InfoMedLinks 2006.

Lung Cancer

Daily Treatment Report

Cognitive Therapy-CBT-Psychotherapy

Device Therapy

Drug Side-Effects and Interactions

Toxicities of antiangiogenic therapy in non-small-cell lung cancer. (lin Lung Cancer. 2006)

Drugs

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. (J Thorac Oncol. 2007)

Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. (J Thorac Oncol. 2007)

[Docetaxel and Cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.] (Gan To Kagaku Ryoho. 2007)

Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer. (Curr Treat Options Oncol. 2007) "OPINION STATEMENT: NSCLC is the leading cause of cancer mortality in the United States. Approximately 30-40% of patients present with advanced stage disease (Stage IIIb with malignant effusion and Stage IV) and the majority of those who present with "earlier" disease will ultimately develop and succumb to metastatic lung cancer. Although platinum-based combination chemotherapy has been shown to impact overall survival and quality of life, it is not curative and less than 25% of patients survive 2 years. Therefore, the benefits of chemotherapy must be weighed against toxicity, inconvenience, and cost."

Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. (J Thorac Oncol. 2007)

Adjuvant chemotherapy for non-small cell lung cancer. (Cancer Invest. 2007)

Adjuvant chemotherapy in non-small cell lung cancer (NSCLC) (Ann Oncol 2007)

Meta-Analysis Suggests Cisplatin Superior to Carboplatin for Advanced NSCLC

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. (J Natl Cancer Inst. 2007)

Adjuvant Chemotherapy for Non-small Cell Lung Cancer (J Thorac Oncol. 2007)

A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer. (J Thorac Oncol. 2007)

Adjuvant Chemotherapy in Elderly Patients with Non-Small-Cell Lung Cancer (Cancer Control. 2007)

Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further? (Oncology (Williston Park). 2007)

Adjuvant Chemotherapy in Non-small Cell Lung Cancer (Int J Clin Pract. 2007)

[Effective combination chemotherapy of Carboplatin and Paclitaxel in the treatment of a recurrent small-cell lung cancer patient.] (Gan To Kagaku Ryoho. 2007)

Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer. (Curr Opin Oncol. 2007) "SUMMARY: Neoadjuvant chemotherapy in early-stage nonsmall-cell lung cancer should not yet be offered outside of clinical trials and will in the future have to be compared with adjuvant chemotherapy."

Exercise

General Information

Staging non-small cell lung cancer. (Cancer Imaging. 2007)

Targeted therapies in small-cell lung cancer. (Expert Opin Ther Targets. 2007) "Small-cell lung cancer is an aggressive form of lung cancer that, overall, remains the most common cause of cancer death in the US. Some advances have been made in the treatment of small-cell lung cancer using cytotoxic chemotherapeutic agents but no truly targeted therapies are available as of yet."

Current treatment paradigms for locally advanced non-small cell lung cancer. (J Thorac Oncol. 2007) "Locally advanced non-small cell lung cancer (NSCLC) is a multifaceted disease that is challenging to manage. The majority of patients can be appropriately treated with a combination of chemotherapy and radiation therapy; however, a subset of stage III patients who are considered surgical candidates may require a modification of this plan."

Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer. (Ann Thorac Surg. 2007)

Gender difference as a prognostic factor in patients undergoing resection of non-small cell lung cancer. (Surg Today. 2007)

PET/CT predicts chemo response in lung cancer patients

[Multidisciplinary management of lung cancer.] (Dtsch Med Wochenschr. 2007)

Limited-stage small-cell lung cancer: therapeutic options. (Oncology (Williston Park). 2007)

Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer? (J Thorac Oncol. 2007)

Study Compares Late-Stage Lung Cancer Treatments "After initial chemotherapy, radiation treatment may be better than surgery for patients with advanced non-small cell lung cancer, a European study finds."

Randomized Trial Finds Radiation Preferred Over Surgery for Patients with Some Stages of Lung Cancer "After an initial chemotherapy treatment, radiation may be a better choice than surgery for patients with stage IIIA non-small-cell lung cancer, according to a randomized controlled trial published in the March 21 Journal of the National Cancer Institute. The authors suggest that a combination of chemotherapy and radiation should be the preferred treatment option for these patients. Approximately 80 percent of all lung cancers are non-small-cell lung cancers (NSCLC), and of those patients diagnosed with NSCLC, about 30 percent have locally advanced stages IIIA or IIIB. … The researchers found that surgery, compared to radiation, did not improve survival after treatment with chemotherapy."

Stage IA non-small cell lung cancer: Vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. (Lung Cancer. 2007)

Treatment options for relapsed small-cell lung cancer. (nticancer Drugs. 2007) "Small-cell lung cancer is a chemo-sensitive disease with a response rate ranging from 70 to 90% for first-line treatment; however, relapses are very common and as a result long-term survival is poor. Chemotherapy has demonstrated a benefit over the best supportive care, even in patients who have relapsed after initial treatment with a platinum-based regimen."

A model for predicting lung cancer response to therapy. (Int J Radiat Oncol Biol Phys. 2007)

Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. (Oncologist. 2007) "Small-cell lung cancer is extremely chemo- and radiosensitive, with a response rate of 80% achieved routinely, but few patients are cured by chemoradiotherapy. In this setting, increased cytotoxic dose intensity might improve cure rates. The finding that response rates in small-cell lung cancer correlate with received cytotoxic dose intensity merely confirms that "less is worse" and "more is better." Within conventional ranges, dose intensity can be increased with the support of hematopoietic growth factors and/or by shortening treatments intervals; however, dose intensity could be increased by only 20%-30%, and a survival advantage has not been clearly demonstrated."

Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. (Lung Cancer. 2007) "CONCLUSION: We found that SNPs in ERCC1 and iASPP were associated with response to chemotherapy or combined chemotherapy and radiotherapy in NSCLC patients. These findings support the notion that genetic variations related to DNA repair or apoptosis may affect the effect of chemotherapy or radiation on NSCLC."

[Retrospective analysis of patients with non-small cell lung cancer in surgical stage.] (ev Port Pneumol. 2006)

Analysis of multidisciplinary lung cancer practice. (Intern Med J. 2007)

Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction. (Chest. 2006) " CONCLUSION: Patients having advanced NSCLC with locally treated malignant central airway obstruction in combination with chemotherapy do not have a worse survival compared to those with advanced NSCLC without central airway obstruction. Therapeutic bronchoscopy should be offered to patients with NSCLC and central airway obstruction."

Guidelines

Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). (Chest. 2007)

Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). (Chest. 2007)

Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). (Chest. 2007)

Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). (Chest. 2007) "BACKGROUND: The treatment of non-small cell lung cancer (NSCLC) is determined by accurate definition of the stage. If there are no distant metastases, the status of the mediastinal lymph nodes is critical. Although imaging studies can provide some guidance, in many situations invasive staging is necessary. Many different complementary techniques are available."

Modern management of small-cell lung cancer. (Drugs. 2007)

Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). (Chest. 2007)

Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). (Chest. 2007)

Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). (Chest. 2007)

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). (Chest. 2007)

Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). (Chest. 2007)

Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). (Chest. 2007)

Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). (Chest. 2007)

New Guidelines Issued on Lung Cancer Diagnosis and Management (2007)

NGC - Management of unresected stage III non-small cell lung cancer: a clinical practice guideline. (2006)

NGC - The role of radiation therapy in malignant pleural mesothelioma: a clinical practice guideline. (2006)

NGC - Nonsurgical, aggressive therapy for non-small-cell lung cancer. (2006)

NGC - Postoperative adjuvant therapy in non-small-cell lung cancer. (2006)

NGC - Chemotherapy for relapsed small cell lung cancer: a clinical practice guideline. (2006)

Immunotherapy

Internet Sites

Treatment Information

DrugBank (drug structure)

FDA - MedWatch (Drug Alerts)

National Comprehensive Cancer Network

NCI - Breast Cancer (PDQ®): Treatment

NCI - Dictionary of Cancer Terms

NCI - Drug Dictionary

NCI - Overview of Nutrition in Cancer Care

Drug-Food-Supplement Information

Drug Information Online

Drug Interaction Checker

DrugDigest (drug interactions)

FDA - Drug Interactions: What You Should Know

NIH - Botanical Dietary Supplements: Background Information

NIH - Drug, Supplements, and Herbal Information

NIH - Herbal Supplements: Consider Safety, Too

NIH - Medicines

NIH - Vitamin and Mineral Supplement Fact Sheets

Nutrition

Nutritional status affects long term survival after lobectomy for lung cancer. (Lung Cancer. 2007)

Circulating 25-Hydroxyvitamin D Levels Predict Survival in Early-Stage Non–Small-Cell Lung Cancer Patients (Journal of Clinical Oncology 2007) "CONCLUSION: Vitamin D may be associated with improved survival of patients with early-stage NSCLC, particularly among stage IB-IIB patients."

Other

Radiation-Chemotherapy

Improving Outcomes for Limited Stage Small Cell Lung Cancer Patients in Scotland with Concomitant Chemoradiation (Clinical Oncology 2007)

[Chemoradiation for locally advanced non-small cell lung cancer.] (Cancer Radiother. 2007)

Other Treatments

Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality Therapy (Journal of Clinical Oncology 2007)

Improving outcomes for limited stage small cell lung cancer patients in Scotland with concomitant chemoradiation. (Clin Oncol (R Coll Radiol). 2007)

Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). ( Clin Oncol. 2007)

6-Year Experience of Concurrent Radiochemotherapy with Vinorelbine Plus a Platinum Compound in Multimorbid or Aged Patients with Inoperable Non-Small Cell Lung Cancer. (Strahlenther Onkol. 2007)

Experimental

The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. (Biochem Biophys Res Commun. 2007) "These data indicate the potential use of EGCG, and possibly green tea, in treating SCLC."

Oral Consumption of Pomegranate Fruit Extract Inhibits Growth and Progression of Primary Lung Tumors in Mice. (Cancer Res. 2007)

Radiotherapy

High-Dose Radiotherapy for the Treatment of Inoperable Non-Small Cell Lung Cancer. (Cancer J. 2007)

Radiotherapy Can Prevent Spread of Small-Cell Lung Cancer to the Brain

[Radiation therapy for lung cancer] (Gan To Kagaku Ryoho. 2007)

Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: case report. (J Neurooncol. 2007)

Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non–Small-Cell Lung Cancer (JNCI Journal of the National Cancer Institute 2007) "Conclusion: In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiotherapy. In view of its low morbidity and mortality, radiotherapy should be considered the preferred locoregional treatment for these patients."

FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. (Lung Cancer. 2007)

Supplements-Vitamins-CAM

Use of complementary and alternative medicine therapies to control symptoms in women living with lung cancer. (Cancer Nurs. 2007)

Surgery

Surgical results and prognosis of patients with primary bronchogenic carcinoma aged less than 36 years. (Respirology. 2007) "The most common presenting symptom was cough (n = 23, 67.7%). Histopathological diagnosis was squamous cell carcinoma (SCC, n = 17), adenocarcinoma (n = 12), lymphoepithelioma-like carcinoma (n = 1) and undifferentiated carcinoma (n = 1). Staging of the 17 patients with SCC (58.8%) was stage I and II (n = 10, 58%), and stage III (n = 7, 41%). Staging of the 13 patients with adenocarcinoma was stage IV (n = 2, 16%) and stage III patients (n = 8, 66%). … Conclusions: SCC comprised a relatively high proportion of NSCLC in these younger patients. Aggressive multimodality treatment may achieve satisfactory 2- and 5-year survival rates in young patients with NSCLC who usually present with advanced disease."

The revolution of thoracotomy for lung cancer surgery. (Ann Thorac Cardiovasc Surg. 2007)

Management of Locally Advanced Non Small Cell Lung Cancer from a Surgical Perspective. (Curr Treat Options Oncol. 2007)

The Role of Surgery in the Treatment of Stage III Non-small-cell Lung Cancer. (Curr Oncol Rep. 2007)

Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude. (Thorax. 2007)

Easier Surgery for Lung Cancer "A smaller incision and less trauma during surgery may make it possible for lung cancer patients to receive more chemotherapy. Patients who are eligible for this type of procedure may have a better chance of beating their cancer, according to a surgeon from Duke University Medical Center."

Clinical Characteristics and Survival of Patients with Surgically Resected, Incidentally Detected Lung Cancer. (J Thorac Oncol. 2007)

Multiple pulmonary metastases of lung adenocarcinoma to a different ipsilateral lobe after pulmonary lobectomy. (Lung Cancer. 2007)

Lobectomy May Be Better Than Wedge Resection for Stage IA Lung Cancers "Lobectomy may provide better survival than wedge resection for lung cancers < 3 cm in size (stage IA), according to a report in the January issue of Chest."

Surgery of non-small cell lung cancer in the elderly. (Curr Opin Oncol. 2007)

Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. (nn Thorac Surg. 2007) "CONCLUSIONS: In our experience, treatment for recurrent nonsmall-cell lung cancer significantly prolongs survival. Various treatment modalities including surgery should be considered in patients with postoperative recurrent nonsmall-cell lung cancer."

Lung cancer resection in octogenarians: a reasonable approach for our aging population. (m Surg. 2007)

Factors causing early relapse after lung metastasis surgery (European Journal of Cancer Care 2007)

Transplantation

Go to the top